BCG Market Access Roundtable Working Group

Why pharma and all stakeholders in the healthcare ecosystem should undertake a fundamental shift in how evidence to support new treatments is generated and assessed.

BCG’s 2022 benchmark study uncovers new competencies needed for pharma access leaders in enterprise-wide business strategy, where thoughtfully designed approaches and goals focused on shared priority and responsibility are increasingly important.

Winning in the 20s: How access needs to evolve.

Examining the key learnings from BCG’s 2019 benchmark study-and the capabilities uncovered that will be critical to future performance.

Key learnings from the BCG Market Access benchmark 2019.

Industry working group identifies the value characteristics that may, collectively, become part of a shared approach to valuing pharmaceutical treatments.

Industry working group identifies the value characteristics that may, collectively, become part of a higher-level, shared approach to valuing pharmaceutical treatments.

While market access functions have evolved, the same can’t be said for measures used to gauge the contribution of these activities on overall business. To that end, an industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

A new industry working group explores alternative drug funding options in Europe-and asks key stakeholders in the region to join the discussion.